{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:05:54Z","timestamp":1764133554982,"version":"3.44.0"},"reference-count":183,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ad.2022.01.040","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T10:48:28Z","timestamp":1653130108000},"page":"T583-T609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["[Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2\u2014Management of Special Populations, Patients With Comorbid Conditions, and Risk"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"J.M.","family":"Carrascosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"L.","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-7320","authenticated-orcid":false,"given":"I.B.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-5469","authenticated-orcid":false,"given":"L.","family":"Salgado-Boquete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-356X","authenticated-orcid":false,"given":"E.","family":"del Alc\u00e1zar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-4752","authenticated-orcid":false,"given":"J.J.A.","family":"Lencina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-7974","authenticated-orcid":false,"given":"D.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-3551","authenticated-orcid":false,"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2022.01.040_bib0920","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/jdv.15177","article-title":"Position statement for the management of comorbidities in psoriasis","volume":"32","author":"Dauden","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib0925","first-page":"225","article-title":"Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: a consensus statement","volume":"112","author":"Belinchon","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2022.01.040_bib0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Dauden","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib0935","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0001-7310(09)70821-X","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology","volume":"100","author":"Puig","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.01.040_bib0940","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ad.2013.04.003","article-title":"Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.01.040_bib0945","unstructured":"European Medicines Agency. Skyrizi 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/skyrizi-0 [Cited 2022 Jan 2]."},{"journal-title":"Actas Dermosifiliogr","year":"2022","author":"Carrascosa","key":"10.1016\/j.ad.2022.01.040_bib0950"},{"key":"10.1016\/j.ad.2022.01.040_bib0955","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1203475419897578","article-title":"Biologic treatment in elderly patients with psoriasis: a systematic review","volume":"24","author":"Sandhu","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2022.01.040_bib0960","first-page":"1","article-title":"The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry","author":"Munera-Campos","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.01.040_bib0965","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jdv.12492","article-title":"Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008\u20132013 results of the Biobadaderm registry","volume":"29","author":"Carretero","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib0970","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1080\/14740338.2016.1226279","article-title":"Efficacy and safety of infliximab in psoriatic patients over the age of 65","volume":"15","author":"Chiricozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ad.2022.01.040_bib0975","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2006.02.010","article-title":"Etanercept for the treatment of psoriasis in the elderly","volume":"55","author":"Militello","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib0980","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jdv.13771","article-title":"Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study","volume":"31","author":"Chiricozzi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib0985","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib0990","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000345623","article-title":"Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study","volume":"225","author":"Esposito","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2022.01.040_bib0995","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"K\u00f6rber","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ad.2022.01.040_bib1000","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ced.12850","article-title":"Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period","volume":"41","author":"Megna","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1010","doi-asserted-by":"crossref","first-page":"AB176","DOI":"10.1016\/j.jaad.2019.06.658","article-title":"Brodalumab in patients with psoriasis ages <65 and 65 years: 120-week findings from two phase 3 studies","volume":"81","author":"Lebwohl","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/1346-8138.13853","article-title":"Biologic treatments for elderly patients with psoriasis","volume":"44","author":"Momose","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1020","doi-asserted-by":"crossref","first-page":"AB120","DOI":"10.1016\/j.jaad.2020.06.570","article-title":"13632 long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials","volume":"83","author":"van de Kerkhof","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1025","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1030","doi-asserted-by":"crossref","first-page":"AB49","DOI":"10.1016\/j.jaad.2019.06.211","article-title":"Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: integrated analysis of two phase 3 trials","volume":"81","author":"Foley","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jdv.15139","article-title":"Elderly psoriatic patients under biological therapies: an Italian experience","volume":"33","author":"Ricceri","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1040","first-page":"846","article-title":"Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis","volume":"14","author":"Garber","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2340\/00015555-1719","article-title":"Efficacy and safety of systemic treatments for psoriasis in elderly patients","volume":"94","author":"Piaserico","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1050","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jdv.12688","article-title":"Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry","volume":"29","author":"Medina","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1060","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.ad.2022.01.040_bib1070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12\u201317 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA \u2013 PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1080","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000096202","article-title":"Anti-TNF-alpha therapy in childhood pustular psoriasis","volume":"213","author":"Pereira","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2022.01.040_bib1090","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/pde.12457","article-title":"Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment","volume":"32","author":"Skrabl-Baumgartner","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.0736-8046.2004.21121.x","article-title":"Successful treatment of pediatric psoriasis with infliximab","volume":"21","author":"Menter","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1100","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jdcr.2019.04.014","article-title":"Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient","volume":"5","author":"Kim","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ad.2022.01.040_bib1105","first-page":"1","article-title":"Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid","volume":"30","author":"Brown","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.01.040_bib1110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/cdli.1.6.667-669.1994","article-title":"Placental transfer of immunoglobulin G subclasses","volume":"1","author":"Garty","year":"1994","journal-title":"Clin Diagn Lab Immunol"},{"issue":"Pt A","key":"10.1016\/j.ad.2022.01.040_bib1115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","article-title":"Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases","volume":"67","author":"Irani","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ad.2022.01.040_bib1120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ecco-jcc\/jjy153","article-title":"Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn's disease","volume":"13","author":"Klenske","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ad.2022.01.040_bib1125","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5114\/ada.2020.102089","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines","volume":"37","author":"Owczarek","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.ad.2022.01.040_bib1130","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to anti-TNF-\u03b1 during pregnancy","volume":"8","author":"Esteve-Sol\u00e9","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ad.2022.01.040_bib1135","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/ard.2008.105924","article-title":"Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum","volume":"68","author":"Murashima","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1140","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/rheumatology\/keq185","article-title":"Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding","volume":"49","author":"Berthelsen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2022.01.040_bib1145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","article-title":"Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer","volume":"116","author":"Porter","year":"2016","journal-title":"J Reprod Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2022.01.040_bib1155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/annrheumdis-2021-eular.577","article-title":"POS0022 pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol: pregnancy outcomes and confounders","volume":"80","author":"Clowse","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1160","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v19.i17.2591","article-title":"Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review","volume":"19","author":"Marchioni","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2022.01.040_bib1165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ad.2022.01.040_bib1170","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3899\/jrheum.140189","article-title":"Pregnancy outcomes in subjects exposed to certolizumab pegol","volume":"42","author":"Clowse","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1175","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1180","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jcpt.12492","article-title":"Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature","volume":"42","author":"Cortes","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ad.2022.01.040_bib1190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000380880","article-title":"Pregnancy during ustekinumab treatment for severe psoriasis","volume":"231","author":"Rocha","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2022.01.040_bib1195","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Gotestam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1200","doi-asserted-by":"crossref","first-page":"104476","DOI":"10.1016\/j.yrtph.2019.104476","article-title":"Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates","volume":"108","author":"Santostefano","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.ad.2022.01.040_bib1205","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.crohns.2011.05.006","article-title":"Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease","volume":"5","author":"Ben-Horin","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ad.2022.01.040_bib1210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/ajd.12641","article-title":"Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration","volume":"59","author":"Rademaker","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2022.01.040_bib1215","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0016-5085(12)60561-7","article-title":"PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy","volume":"142","author":"Mahadevan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2022.01.040_bib1220","first-page":"1","article-title":"Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab","author":"Egeberg","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.01.040_bib1225","unstructured":"Guselkumab. Drugs and lactation database (LactMed). Bethesda (MD); 2006."},{"key":"10.1016\/j.ad.2022.01.040_bib1230","unstructured":"Sanitarios AEdMyP. Ficha t\u00e9cnica_Guselkumab 2017."},{"key":"10.1016\/j.ad.2022.01.040_bib1235","unstructured":"Sanitarios AEdMyP. Ficha t\u00e9cnica_Adalimumab 2008."},{"key":"10.1016\/j.ad.2022.01.040_bib1240","first-page":"1017","article-title":"Etanercept in breast milk","volume":"31","author":"Ostensen","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1245","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","article-title":"Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study","volume":"76","author":"Clowse","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1250","unstructured":"Eurpean Medicines Agency. Bimzelx 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_es.pdf [Cited 2022 Jan 2]."},{"key":"10.1016\/j.ad.2022.01.040_bib1255","unstructured":"Eurpean Medicines Agency. Ilumetri 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilumetri-epar-product-information_es.pdf [Cited 2022 Jan 2]."},{"key":"10.1016\/j.ad.2022.01.040_bib1260","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1265","first-page":"864","article-title":"Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis","volume":"14","author":"Prussick","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1270","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.autrev.2016.01.010","article-title":"Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy","volume":"15","author":"Iannone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ad.2022.01.040_bib1275","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjd.16008","article-title":"Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"178","author":"Gordon","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1280","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/jdv.16187","article-title":"Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2 b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis","volume":"34","author":"Poulin","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1285","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ad.2022.01.040_bib1290","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1295","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/jdv.14252","article-title":"The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1305","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.reuma.2017.08.007","article-title":"Recomendaciones de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el tratamiento y uso de terapias sist\u00e9micas biol\u00f3gicas y no biol\u00f3gicas en artritis psori\u00e1sica","volume":"14","author":"Torre Alonso","year":"2018","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ad.2022.01.040_bib1310","doi-asserted-by":"crossref","first-page":"618163","DOI":"10.3389\/fmed.2020.618163","article-title":"A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains","volume":"7","author":"Torres","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ad.2022.01.040_bib1315","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ad.2020.06.004","article-title":"El papel del dermat\u00f3logo en el diagn\u00f3stico precoz de la artritis psori\u00e1sica: recomendaciones de un grupo de expertos","volume":"111","author":"Belinch\u00f3n","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.01.040_bib1320","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjd.14528","article-title":"Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1325","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaad.2017.06.043","article-title":"Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation","volume":"78","author":"Whitlock","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1330","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1093\/ibd\/izz033","article-title":"A case report of successful treatment of Crohn's disease and psoriasis with guselkumab","volume":"25","author":"Grossberg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1335","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ad.2022.01.040_bib1340","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ad.2022.01.040_bib1345","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2022.01.040_bib1350","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression","volume":"31","author":"Koo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1355","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1360","unstructured":"European Medicines Agency. Kyntheum2020 22 Jun 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kyntheum [Cited 2022 Jan 2]."},{"key":"10.1016\/j.ad.2022.01.040_bib1365","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bjd.14837","article-title":"Motivational interviewing-based training enhances clinicians\u2019 skills and knowledge in psoriasis: findings from the Pso Well\u00ae study","volume":"176","author":"Chisholm","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1370","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1375","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000000865","article-title":"Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy","volume":"53","author":"Micic","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ad.2022.01.040_bib1380","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2022.01.040_bib1385","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1390","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1395","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1400","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxf, Engl)"},{"key":"10.1016\/j.ad.2022.01.040_bib1405","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1210\/jc.2010-1170","article-title":"TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome","volume":"96","author":"Stanley","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ad.2022.01.040_bib1410","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ad.2022.01.040_bib1415","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00403-007-0784-3","article-title":"Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus","volume":"299","author":"Martinez-Abundis","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ad.2022.01.040_bib1420","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archdermatol.2012.1753","article-title":"Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis","volume":"148","author":"Kofoed","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1425","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1430","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","article-title":"Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis","volume":"31","author":"Pinter","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.01.040_bib1435","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2022.01.040_bib1440","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ad.2016.12.017","article-title":"Psoriasis and nonalcoholic fatty liver disease","volume":"108","author":"Carrascosa","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.01.040_bib1445","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ad.2022.01.040_bib1450","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.ad.2022.01.040_bib1455","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00125-019-4962-6","article-title":"Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis","volume":"62","author":"Herrero-Cervera","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.ad.2022.01.040_bib1460","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3892\/etm.2021.11075","article-title":"Cardiovascular comorbidities in psoriasis (Review)","volume":"23","author":"Branisteanu","year":"2022","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ad.2022.01.040_bib1465","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ad.2022.01.040_bib1470","doi-asserted-by":"crossref","first-page":"e000763","DOI":"10.1136\/rmdopen-2018-000763","article-title":"Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials","volume":"5","author":"Champs","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.ad.2022.01.040_bib1475","first-page":"823","article-title":"Kidney disease and psoriasis. a new comorbidity?","volume":"107","author":"Gonzalez-Parra","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.01.040_bib1480","first-page":"809","article-title":"Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study","volume":"95","author":"Svedbom","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1485","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1490","article-title":"Renal dysfunction in psoriatic patients","volume":"37","author":"Grandinetti","year":"2020","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.ad.2022.01.040_bib1495","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ad.2022.01.040_bib1500","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.ad.2022.01.040_bib1505","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/09546634.2012.660520","article-title":"Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature","volume":"24","author":"Mahil","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.01.040_bib1510","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2022.01.040_bib1515","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bjd.18327","article-title":"Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials","volume":"182","author":"Hsu","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1520","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"T Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1525","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Ostor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1530","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.ad.2022.01.040_bib1535","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2022.01.040_bib1540","unstructured":"European Medicines Agency. Cosentyx 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_es.pdf [Cited 2022 Jan 2]."},{"key":"10.1016\/j.ad.2022.01.040_bib1545","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.ad.2022.01.040_bib1550","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2022.01.040_bib1555","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/rheumatology\/keab329","article-title":"\u2018Too much of a good thing\u2019: can network meta-analysis guide treatment decision-making in psoriatic arthritis?","volume":"60","author":"Marzo-Ortega","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2022.01.040_bib1560","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.180797","article-title":"Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis","volume":"47","author":"Mourad","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1565","first-page":"508","article-title":"Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes","volume":"38","author":"Simons","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1570","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1093\/rheumatology\/keaa313","article-title":"Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis","volume":"59","author":"Wu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2022.01.040_bib1575","first-page":"1","article-title":"Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations","volume":"12","author":"Galluzzo","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2022.01.040_bib1580","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2011.06.011","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1585","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1590","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1595","series-title":"Annual coastal dermatology symposium; October 15; E-congress","article-title":"Maintenance of response through 5 years of continuous guselkumab treatment: results from the phase 3 VOYAGE 1 trial","author":"Griffiths","year":"2020"},{"key":"10.1016\/j.ad.2022.01.040_bib1600","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris \u2013 Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1605","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1055\/s-2008-1027411","article-title":"Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH)","volume":"46","author":"Schramm","year":"2008","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.ad.2022.01.040_bib1610","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/jid.2015.87","article-title":"Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink","volume":"135","author":"Parisi","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1615","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjd.12118","article-title":"Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1620","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1625","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ad.2022.01.040_bib1630","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","article-title":"Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"141","author":"Gonzalez-Cantero","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1635","doi-asserted-by":"crossref","first-page":"e011199","DOI":"10.1161\/CIRCIMAGING.120.011199","article-title":"Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective observational study","volume":"13","author":"Choi","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ad.2022.01.040_bib1640","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1684\/ejd.2015.2558","article-title":"Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-alpha therapy in psoriatic arthritis","volume":"25","author":"Honda","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1645","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.ad.2022.01.040_bib1650","series-title":"Short and long term safety of risankizumab in patients with moderate to severe psoriasis: an integrated analysis","first-page":"37","author":"Bachelez","year":"2019"},{"key":"10.1016\/j.ad.2022.01.040_bib1655","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.06.004","article-title":"To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis","volume":"73","author":"Ahn","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1660","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1665","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jaad.2019.12.033","article-title":"Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea","volume":"82","author":"Cho","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1670","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1675","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1680","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jdv.16460","article-title":"Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials","volume":"34","author":"Puig","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1685","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1690","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/14712598.2020.1822813","article-title":"Update on risankizumab for the treatment of moderate to severe psoriasis","volume":"20","author":"Al-Janabi","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2022.01.040_bib1695","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/09546634.2018.1544413","article-title":"Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis","volume":"30","author":"Plachouri","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.01.040_bib1700","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2013.06.046","article-title":"From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis","volume":"69","author":"Wine-Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1705","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3748\/wjg.v27.i19.2312","article-title":"Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics","volume":"27","author":"Akiyama","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2022.01.040_bib1710","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1715","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/09546634.2018.1535690","article-title":"Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study","volume":"30","author":"Montes-Torres","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2022.01.040_bib1720","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/vaccines8040769","article-title":"Immune response to vaccination in patients with psoriasis treated with systemic therapies","volume":"8","author":"Chiricozzi","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ad.2022.01.040_bib1725","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ad.2020.05.004","article-title":"Recomendaciones del Grupo de Psoriasis de la AEDV sobre el manejo de la consulta de psoriasis durante la pandemia por COVID-19","volume":"111","author":"Belinch\u00f3n","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2022.01.040_bib1730","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s15010-018-1189-2","article-title":"Subclinical Leishmania infection in patients with rheumatic diseases under biological drugs","volume":"46","author":"Maritati","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.ad.2022.01.040_bib1735","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.cmi.2015.05.033","article-title":"Immunosuppression and Chagas disease; experience from a non-endemic country","volume":"21","author":"Salvador","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ad.2022.01.040_bib1740","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","article-title":"Immunogenicity of biologic therapies: causes and consequences","volume":"14","author":"Boehncke","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ad.2022.01.040_bib1745","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach","volume":"35","author":"Tsakok","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1750","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1755","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1760","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1765","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2022.01.040_bib1770","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1775","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","article-title":"The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"176","author":"Griffiths","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1780","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jdv.14605","article-title":"Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study","volume":"32","author":"Gerdes","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2022.01.040_bib1785","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1790","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jid.2019.02.018","article-title":"Immunogenicity of guselkumab is not clinically relevant in patients with moderate-to-severe plaque psoriasis","volume":"139","author":"Zhu","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1795","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.ad.2022.01.040_bib1800","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1805","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjd.14965","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis","volume":"176","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1810","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/bjd.17918","article-title":"Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab","volume":"182","author":"Kimball","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2022.01.040_bib1815","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.ad.2022.01.040_bib1820","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2022.01.040_bib1825","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.ad.2022.01.040_bib1830","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet (Lond, Engl)"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102200415X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102200415X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:13:32Z","timestamp":1757553212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173102200415X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":183,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S000173102200415X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2022.01.040","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2\u2014Management of Special Populations, Patients With Comorbid Conditions, and Risk","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2022.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2022.01.024","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}